Evidence map›Paper›PMID 37452631›Full record

Trial reportPharmacotherapy2023

Bayesian optimization of tacrolimus exposure in stable kidney transplant patients.

Thomas D Nguyen, Nicholas M Smith, Kris Attwood, Aijaz Gundroo, Shirley Chang, Mahfuz Yonis, Brian Murray, Kathleen M Tornatore

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pharmacotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Whole-body distribution of threeAntimicrobial agents and chemotherapy · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Thomas D NguyenSchool of Pharmacy & Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.ORCID 0009-0000-1069-1720
Nicholas M SmithSchool of Pharmacy & Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.ORCID 0000-0002-0212-2787
Kris AttwoodBiostatistics, School of Public Health and Health Professions, Buffalo, New York, USA.ORCID 0000-0002-7229-5472
Aijaz GundrooDivision of Nephrology, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.
Shirley ChangDivision of Nephrology, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.
Mahfuz YonisDivision of Nephrology, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.
Brian MurrayDivision of Nephrology, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.
Kathleen M TornatoreSchool of Pharmacy & Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.ORCID 0000-0003-2028-4998
Erie County Medical Center · USPediatric Nephrology of Alabama · USUniversity at Buffalo, State University of New York · US

Funding

University of Buffalo Clinical and Translational Science Institute - Supplement SchulyerUL1TR001412 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 2015 to 2024
$33.8M
Age and Race Influences on Immunosuppression after Renal TransplantR01AG056392 · NIA · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI TORNATORE, KATHLEEN M · 2018 to 2022
$3.5M
Genomic and Cellular Markers and Chronic Renal Allograft FunctionR21DK077325 · NIDDK · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI TORNATORE, KATHLEEN M · 2009 to 2010
$427k
NCATS NIH HHS UL1 TR001412NCATS NIH HHS UL1TR001412 (Subaward PS-Smith)NIAID NIH HHS L30 AI164450NIA NIH HHS R01 AG056392NIA NIH HHS R01AG056392NIDDK NIH HHS R21 DK077325NIDDK NIH HHS R21DK077325
6 · The paper itself

Abstract

STUDY

objectiveThe objective was to compare tacrolimus AUC

designThis open-label, prospective, single center 12-h PK study included nine serial samples collected in KTRs to determine steady-state NCA tacrolimus AUC

settingThis study was conducted at a single site within a large, urban hospital in the western New York area. PATIENTS: This study described tacrolimus pharmacokinetics in stable kidney transplant recipients on maintenance tacrolimus therapy.

interventionRobust and sparse AUC MEASUREMENTS AND MAIN

resultsA total of 35 Black and 32 White stable KTRs (estimated glomerular filtration rate [eGFR] = 55.2 ± 15.7 mL/min/1.73m

conclusionMAP-Bayesian estimation for patient-specific AUC

Indexed as

Kidney TransplantationTacrolimusArea Under CurveBayes TheoremHumansImmunosuppressive AgentsProspective StudiesImmunosuppressive AgentsTacrolimusimmunosuppressionkidney transplantationmaximum a priori-Bayesiannon-compartmental analysistacrolimus pharmacokinetics

Identifiers

PMID37452631
PMCPMC10592415
OpenAlexW4384401322

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.